Sun Pharma Receives EIR for Halol Facility

Sun Pharmaceutical Industries Ltd. announced that it has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018. The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed. Commenting on the development, Dilip Shanghvi, Managing Director, Sun Pharma said, “This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24×7 cGMP compliance at all our manufacturing facilities globally.” – Medical Buyer Bureau